These findings suggest two translational opportunities: (i) FLI1 could be used as a pharmacodynamic biomarker of breast cancer metastastatic potential, capturing stromal and immune remodeling, and (ii) combining direct FLI1 inhibition and LSD1 blockade may yield stnergistic therapeutic effects. The gene discussed is FLI1; the disease is breast carcinoma.